LENZ Therapeutics

Renee Bovelle, MD is confident about recent data in the space, knowing how a small pupil affects depth-of-focus. “As clinicians, it’s important for us to stay in-the-know about emerging treatments. A potential presbyopia solution that targets the ideal pupil size isn't only something that every clinician should be aware of, it’s also something they should be confident about implementing into their practice.” www.EyeAmSelective.com #EyeAmSelective #Presbyopia

Following its public debut in March, LENZ Therapeutics is excited to now be part of the #Russell2000Index, which is one of the most widely used benchmarks for small-cap stocks. INDEXRUSSELL: LENZ   Learn more here: https://lnkd.in/g7PDi3rP

Mile Brujic is encouraged by the data of emerging presbyopia solutions, knowing that the details matter for presbyopic patients. “Details matter when it comes to vision. Extending depth of focus through reducing pupil size makes me optimistic for my presbyopic patients.” Are you following the latest research? Visit us at www.EyeAmSelective.com to learn more. #EyeAmSelective #Presbyopia

LENZ Therapeutics was thrilled with the excitement at our capacity capped Key Opinion Leader (KOL) medical meeting in Nashville last night. Thank you to the panel of investigators, Marc Bloomenstein,O.D., Milton Hom, O.D., Natasha Hindman, O.D., from our Phase 3 CLARITY trial who shared their perspectives on Aceclidine, S. Barry Eiden for moderating the panel and the 100+ ECPs who joined us at the event overlooking Nashville downtown. Make sure to stop by Booth #1103 at the American Optometric Association convention today to learn more about the future of presbyopia solutions. #Presbyopia

The American Optometric Association meeting begins in just a few minutes. Make sure to stop by booth #1103 to visit the LENZ Therapeutics team and learn more about the future of presbyopia solutions or visit EyeAmSelective.com #AOA #Presbyopia #EyeAmSelective

LENZ Therapeutics was excited to host our Key Opinion Leader Event in NY! At the event we presented our Capstone CLARITY data and Principal Investigators Dr. Jason Bacharach, M.D., Dr. Marc Bloomenstein and O.D., Dr. Milton Hom, O.D. shared their real-world perspectives on LNZ100 from the Phase 3 study. Watch the webcast replay here: https://lnkd.in/eFCQZmiQ Downloaded the presentation here: https://lnkd.in/eQeaZN4w

Marc Bloomenstein, OD is motivated to discuss emerging solutions in presbyopia care with his patients. “Patients expect us to provide them with the tools for seamless vision. I’m motivated to manage every patient to their fullest potential, which further motivates me to discuss and provide new and emerging solutions to solve refractive obstacles. Visit LENZ at booth #1103 at American Optometric Association, June 19th – 22nd in Nashville, and share your voice about the future of presbyopia solutions. www.EyeAmSelective.com #presbyopia #EyeAmSelective #AOA

LENZ Therapeutics to host Key Opinion Leader Event on June 18, 2024. The event will highlight real-world insights by Key Opinion Leaders and Principal Investigators on the current treatment landscape for presbyopia and their perspectives on LNZ100 data from the Phase 3 CLARITY study. Read full press release here:

LENZ Therapeutics to host Key Opinion Leader Event on June 18, 2024. The event will highlight real-world insights by Key Opinion Leaders and Principal Investigators on the current treatment landscape for presbyopia and their perspectives on LNZ100 data from the Phase 3 CLARITY study. Read full press release here: https://lnkd.in/gybQgKpy

LENZ Therapeutics welcomes Melody Burcar as Vice President, Finance. Melody has worked in the San Diego life sciences community for over 15 years. She was most recently the Senior Vice President at Viracta Therapeutics. Melody brings great depth of financing and accounting knowledge, SEC experience, and most importantly great commercial financial planning and 3PL/commercial experience. Join us in welcoming Melody to the team!